Pharmacodynamic biomarkers for molecular cancer therapeutics
about
sameAs
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical modelsAntitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastomaCirculating Tumor Cell Isolation and Analysis.Molecular imaging agents: impact on diagnosis and therapeutics in oncologyA review of imaging techniques for systems biology.A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.An integrative paradigm to impart quality to correlative science.Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer.Identification and validation of inhibitor-responsive kinase substrates using a new paradigm to measure kinase-specific protein phosphorylation indexS-glutathionylated serine proteinase inhibitors as plasma biomarkers in assessing response to redox-modulating drugsDevelopment of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus ErythematosusMonitoring molecular-specific pharmacodynamics of rapamycin in vivo with inducible Gal4->Fluc transgenic reporter mice.Pharmacodynamic modelling of biomarker data in oncology.Target validation using chemical probes.Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.Drugging the PI3 kinome: from chemical tools to drugs in the clinic.Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours.γ-H2AX and other histone post-translational modifications in the clinic.Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy.Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.Biomarker method validation in anticancer drug developmentCancer nanomedicines: so many papers and so few drugs!The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.Reporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials.The interaction between prognostic and pharmacodynamic biomarkers.Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941From darkness to light with biomarkers in early clinical trials of cancer drugs.Biomarkers of apoptosis.Dose-biomarker-response modeling of the anticancer effect of ethaselen in a human non-small cell lung cancer xenograft mouse model.Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.HER3 mRNA as a predictive biomarker in anticancer therapy.Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs.The evolution of imaging in cancer: current state and future challenges.MR evaluation of response to targeted treatment in cancer cells.Analysis of protein biomarkers in human clinical tumor samples: critical aspects to success from tissue acquisition to analysis.Improving the outcomes: developing cancer therapeutics.
P2860
Q27853067-C817AE8B-8191-466E-AD7C-7C940C22611BQ28472048-8E9A067F-AE8B-4283-8264-29B4C0463FB4Q30358229-9E909D82-CCE3-49F7-93C6-4A5BCE1B90AEQ30433423-B1FF1408-0DF1-4C06-841F-1332E1D7FA49Q30493514-5BB9AFAE-05A9-4010-AE73-D615567B5CBEQ31010361-19507635-7EA0-44C7-88F1-219027E045E9Q33551899-FD42C180-3CFE-4133-AB12-0A4FE071B6C8Q33765942-485EFAF2-F614-40D3-9938-20B7317B15ACQ34008787-D19AB93D-97E6-4F49-A6C8-720AF2C53369Q34049848-6C970DF8-FB70-4100-8EA0-159612E6DA0AQ34117297-26219F90-8E24-4F14-BDEA-2E0302E9891DQ34177087-FEF67304-261C-47F8-99B9-371ACE472B6AQ34192264-C07D87AE-28D4-4F3E-8911-21A26E37E926Q34241935-B197591C-6590-4179-B55C-45504389295CQ34333826-4912A463-BB84-4735-B220-08F36E5D9492Q35287729-37BB281E-FAC1-4275-91F1-4D18B20DF00BQ35622141-394DB68E-AF9D-49BE-BF6F-50B5F201812BQ35653933-EE24BBCF-9543-4E88-B6BF-B1216EF62B7BQ36019818-2C90033E-4242-4419-A503-2198798C47D9Q36181578-C74CD948-3088-4CA6-B8A1-78001FFBD9BDQ36361812-461CE3A6-9E02-469C-9FC4-2BF1FA00AC07Q36392598-2C79ECD9-EF98-4BAD-A699-1BE8BF28A04EQ36484621-7F5D7073-657A-4E99-86A7-20DC97FAA352Q36589023-ACE5E11A-F081-4218-88CE-517D4A0B2501Q36771796-F494AE6A-747F-4714-B7C6-BF7EE49F09DBQ36914483-591CEE84-D6C3-4FA2-B3FF-BF7B48560686Q37094837-31747F50-1112-4F86-A398-045E976AC453Q37111197-67A86AAB-6433-48FA-A79A-B5273294DD25Q37214321-36628F3F-A889-45CE-9C6C-1F977EB14CB3Q37281824-BC24180F-A711-43EE-A98A-6998C462A34BQ37371582-2957672D-0032-4CBB-9A98-4B59DB0E1E42Q37400048-9DBD7CFB-0411-4DF8-AB17-8411B94A8479Q37642550-FAFC8051-96F4-4E47-9C0C-D1E0B794D285Q37660266-F9ABA418-AC8F-42DB-9090-63EE429B4486Q37778843-42F8C46A-BA26-4FAD-A0BC-C18C294B6A33Q37798159-030E444E-17CA-408B-A739-6CCA27C2F998Q37848518-6CBACF8A-D3C8-4D17-9DF5-051E4D3424D5Q37851076-3CED43EF-1AD1-4399-B245-8E8DB9DB6A80Q37862749-7B07A0F2-2D8B-4535-B025-52C708594EBBQ37965556-F4F5EA08-9D0B-42E6-90C3-6EE646075BC1
P2860
Pharmacodynamic biomarkers for molecular cancer therapeutics
description
2006 nî lūn-bûn
@nan
2006 թուականին հրատարակուած գիտական յօդուած
@hyw
2006 թվականին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Pharmacodynamic biomarkers for molecular cancer therapeutics
@ast
Pharmacodynamic biomarkers for molecular cancer therapeutics
@en
Pharmacodynamic biomarkers for molecular cancer therapeutics
@nl
type
label
Pharmacodynamic biomarkers for molecular cancer therapeutics
@ast
Pharmacodynamic biomarkers for molecular cancer therapeutics
@en
Pharmacodynamic biomarkers for molecular cancer therapeutics
@nl
altLabel
Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics
@en
prefLabel
Pharmacodynamic biomarkers for molecular cancer therapeutics
@ast
Pharmacodynamic biomarkers for molecular cancer therapeutics
@en
Pharmacodynamic biomarkers for molecular cancer therapeutics
@nl
P1476
Pharmacodynamic Biomarkers for Molecular Cancer Therapeutics
@en
Pharmacodynamic biomarkers for molecular cancer therapeutics
@en
P2093
Debashis Sarker
P356
10.1016/S0065-230X(06)96008-4
P407
P50
P577
2006-01-01T00:00:00Z
2007-01-01T00:00:00Z